San Francisco Sentry Investment Group CA Has $218,000 Position in Eli Lilly and Co (LLY)

San Francisco Sentry Investment Group CA lifted its holdings in Eli Lilly and Co (NYSE:LLY) by 61.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,540 shares of the company’s stock after acquiring an additional 964 shares during the period. San Francisco Sentry Investment Group CA’s holdings in Eli Lilly and were worth $218,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the stock. Accredited Investors Inc. lifted its stake in Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after purchasing an additional 14 shares during the last quarter. Oakworth Capital Inc. raised its stake in shares of Eli Lilly and by 0.3% during the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after acquiring an additional 20 shares in the last quarter. Sfmg LLC raised its stake in shares of Eli Lilly and by 0.5% during the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after acquiring an additional 20 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in shares of Eli Lilly and by 0.7% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock valued at $300,000 after acquiring an additional 24 shares in the last quarter. Finally, YorkBridge Wealth Partners LLC raised its stake in shares of Eli Lilly and by 0.8% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock valued at $265,000 after acquiring an additional 24 shares in the last quarter. 76.30% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently weighed in on LLY shares. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price target on shares of Eli Lilly and in a research note on Monday, September 11th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $84.23 to $88.00 in a research note on Tuesday, October 10th. BMO Capital Markets reissued an “underperform” rating and set a $71.00 price objective (down from $73.00) on shares of Eli Lilly and in a report on Wednesday, September 6th. Piper Jaffray Companies reissued an “overweight” rating and set a $105.00 price objective (up from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Finally, Berenberg Bank reissued a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and an average target price of $90.25.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold 456,088 shares of company stock worth $39,837,286 over the last three months. Corporate insiders own 0.20% of the company’s stock.

Shares of Eli Lilly and Co (LLY) opened at $84.46 on Friday. The firm has a market cap of $92,998.48, a price-to-earnings ratio of 40.03, a PEG ratio of 1.74 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 1-year low of $73.23 and a 1-year high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 earnings per share. analysts predict that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.66%. Eli Lilly and’s payout ratio is 98.58%.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/31/san-francisco-sentry-investment-group-ca-has-218000-position-in-eli-lilly-and-co-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit